Zhou and co-workers reported that HSP90 CTD domain inhibitor novobiocin resulted in proteasomal degradation of Bclaf, reduced c-Myc mRNA and inhibited hepatocellular carcinoma growth, suggesting that targeting HSP90 CTD domain may be a promising strategy for tumors with Bclaf upregulation (51). The gene discussed is HSP90AA1; the disease is hepatocellular carcinoma.